T-2 toxin and its cardiotoxicity: New insights on the molecular mechanisms and therapeutic implications

Chongshan Dai1, Subhajit Das Gupta2, Zhanhui Wang1

  • 1College of Veterinary Medicine, China Agricultural University, No.2 Yuanmingyuan West Road, Beijing, 100193, PR China; Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, Beijing, 100193, PR China.

Insights

T-2 toxin, a common mycotoxin, causes heart damage through cell death and fibrosis. Potential treatments include antioxidants, autophagy inducers, and anti-inflammatory agents to protect against T-2 toxin cardiotoxicity.

Area of Science:

  • Toxicology
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • T-2 toxin is a prevalent and highly toxic trichothecene mycotoxin.
  • Exposure to T-2 toxin is linked to various cardiovascular diseases.
  • Understanding T-2 toxin's cardiotoxic effects is crucial for public health.

Purpose of the Study:

  • To review current knowledge on T-2 toxin-induced cardiotoxicity.
  • To explore the molecular mechanisms underlying T-2 toxin's cardiac damage.
  • To discuss potential therapeutic strategies for T-2 toxin cardiotoxicity.

Main Methods:

  • Literature review of T-2 toxin cardiotoxicity studies.
  • Analysis of pathological findings in T-2 toxin-exposed hearts.
  • Examination of molecular pathways involved in T-2 toxin-induced cardiac damage.

Main Results:

  • T-2 toxin causes cardiomyocyte injury, death, capillary leakage, hemorrhage, and inflammation.
  • Cardiac fibrosis and subsequent cardiac dysfunction are consequences of T-2 toxin exposure.
  • Key mechanisms include oxidative stress, mitochondrial dysfunction, ER stress, and altered signaling pathways (PPAR-γ, TGF-β1/Smad2/3).

Conclusions:

  • T-2 toxin induces significant cardiac pathology through multiple molecular pathways.
  • Antioxidants, autophagy inducers, anti-inflammatory agents, and PPAR-γ agonists show potential protective effects.
  • Further research can lead to effective prevention and treatment strategies for T-2 toxin-induced cardiotoxicity.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
712
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
839
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
20
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
503
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
28